20:12 EDT 22nd June 2018 | BioPortfolio

A pioneer in the field when launched in 1992, Drug Royalty was the first firm to provide royalty-based financing in the life sciences sector and the first to complete royalty transactions with inventors and institutions. Drug Royalty has completed more than 20 transactions and invested in excess of $100 million since its inception


M5J 2J3


Phone: 416-863-1865
Fax: 416-863-5161

News Articles [955 Associated News Articles listed on BioPortfolio]

Albireo sells HealthCare Royalty Partners its elobixibat royalty rights in Japan

Albireo Pharma Inc., through its Elobix subsidiary, entered into an agreement with HealthCare Royalty Partners to monetize its royalty rights for the constipation drug elobixibat in Japan.

La Jolla inks royalty deal to support Giapreza launch

The biotech is tapping HealthCare Royalty Partners for $125 million in near-term cash in exchange for royalty payments later. 

Agenus enters $230mm royalty sale agreement with Healthcare Royalty

Immuno-oncology firm Agenus Inc. entered a $230mm royalty sale agreement with Healthcare Royalty Partners, which will pay $190mm in cash up front in exchange for royalties Agenus is eligible to receiv...

La Jolla Pharma sells HCR Giapreza royalty rights

La Jolla Pharmaceutical Co. sold tiered royalty rights for its Giapreza (angiotensin II) to HealthCare Royalty Partners in exchange for $125mm.

Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan

— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03,...

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended t...

Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million

Royalty Pharma acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU-132) Across All Indications for $175 Million Royalty Pharma Acquires $75 Million of Immunomedics Common S...

HealthCare Royalty in vaccine royalty deal with Agenus

PubMed Articles [2257 Associated PubMed Articles listed on BioPortfolio]

Investigating the correlation between wastewater analysis and roadside drug testing in South Australia.

The societal impact of drug use is well known. An example is when drug-intoxicated drivers increase the burden on policing and healthcare services.

Progress in Research Drug Eluting Stents Drug-looding and Drug Release Kinetics.

Drug eluting stents are one of the main devices of coronary intervention, which play a therapeutic role through the combination of medical devices. Drug is an important part of the drug eluting stents...

Preventable adverse drug events in critically ill HIV patients: Is the detection of potential drug-drug interactions a useful tool?

The aim of this study was to develop a strategy to identify adverse drug events associated with drug-drug interactions by analyzing the prescriptions of critically ill patients.

A qualitative examination of the effects of international counter-drug interdictions.

The purpose of this study is to utilize unique qualitative data to determine the effects of sporadic international drug interdictions on drug trafficking, and to assess whether the responses of drug t...

Drug-drug interactions. Things to do in pain management.

Clinical Trials [2110 Associated Clinical Trials listed on BioPortfolio]

Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens

The joint status (knees, ankles) of patients suffering from severe Hemophilia A (too little blood clotting factor VIII in blood) is evaluated in a single magnetic resonance imaging session...

To Develop a Validated Program and Use it to Evaluate Patients Post-operatively

Annually, the Department of Anesthesiology, Siriraj hospital has responsibilities to take care of more than 50,000 patients peri-operatively. According to Maslow's hierarchy of needs; huma...

Intra-patient Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT (Optical Coherence Tomography) Follow up

The objective of the study is to evaluate the process of early re-endothelialization of the Coroflex® ISAR Drug-eluting stent compared with the Ultimaster® Drug-eluting stent

Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions

The investigators hypothesize that in a real-world population undergoing percutaneous coronary intervention (PCI) for de-novo stenoses in small native vessels with a diameter

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

The purpose of this study is to determine the safety of AZX100 Drug Product and to determine whether it is effective in preventing or reducing re-growth of surgically removed keloid scars.

Companies [1449 Associated Companies listed on BioPortfolio]


A pioneer in the field when launched in 1992, Drug Royalty was the first firm to provide royalty-based financing in the life sciences sector and the first to complete royalty transactions with invento...

Drug Royalty

Drug Royalty is an innovative and profitable Canadian company involved in the international life science industry. Established in 1992, DRC was designed to participate in the growth from the global he...

DRI Capital Inc.

DRI is a pioneer and global leader in healthcare royalty investing and has completed transactions with large global pharmaceutical companies, biotechnology companies, universities...

Capital Royalty L.P.

Our diversified team of investment professionals is dedicated to meeting the specific needs of each client, and with our extensive experience in the healthcare and financial industries, Capital Royalt...

Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners is a global healthcare private equity firm that invests principally in commercial-stage biopharmaceutical and medical device companies and products, through the purch...

More Information about "DRUG ROYALTY CORPORATION INC" on BioPortfolio

We have published hundreds of DRUG ROYALTY CORPORATION INC news stories on BioPortfolio along with dozens of DRUG ROYALTY CORPORATION INC Clinical Trials and PubMed Articles about DRUG ROYALTY CORPORATION INC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DRUG ROYALTY CORPORATION INC Companies in our database. You can also find out about relevant DRUG ROYALTY CORPORATION INC Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record